Health economic impact of liquid biopsies in cancer management.
Loading...
Embargo End Date
ICR Authors
Authors
IJzerman, MJ
Berghuis, AMS
de Bono, JS
Terstappen, LWMM
Berghuis, AMS
de Bono, JS
Terstappen, LWMM
Document Type
Journal Article
Date
2018-11-02
Date Accepted
Abstract
Liquid biopsies (LBs) are referred to as the sampling and analysis of non-solid tissue, primarily blood, as a diagnostic and monitoring tool for cancer. Because LBs are largely non-invasive, they are a less-costly alternative for serial analysis of tumor progression and heterogeneity to facilitate clinical management. Although a variety of tumor markers are proposed (e.g., free-circulating DNA), the clinical evidence for Circulating Tumor Cells (CTCs) is currently the most developed. Areas covered: This paper presents a health economic perspective of LBs in cancer management. We first briefly introduce the requirements in biomarker development and validation, illustrated for CTCs. Second, we discuss the state-of-art on the clinical utility of LBs in breast cancer in more detail. We conclude with a future perspective on the clinical use and reimbursement of LBs Expert commentary: A significant increase in clinical research on LBs can be observed and the results suggest a rapid change of cancer management. In addition to studies evaluating clinical utility of LBs, a smooth translation into clinical practice requires systematic assessment of the health economic benefits. This paper argues that (early stage) health economic research is required to facilitate its clinical use and to prioritize further evidence development.
Citation
Expert review of pharmacoeconomics & outcomes research, 2018, 18 (6), pp. 593 - 599
Source Title
Publisher
TAYLOR & FRANCIS LTD
ISSN
1473-7167
eISSN
1744-8379
Collections
Research Team
Prostate Cancer Targeted Therapy Group